DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair
Pharmaceutics · 12.12.2023 · 15 (12) · 2761
DOI: 10.3390/pharmaceutics15122761 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 12.12.2023. Verfasst von Yousef Khazaei Monfared und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114…. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
DNA is an organic molecule that is highly vulnerable to chemical alterations and breaks caused by both internal and external factors. Cells possess complex and advanced mechanisms, including DNA repair, damage tolerance, cell cycle checkpoints, and cell death pathways, which together minimize the potentially harmful effects of DNA damage. However, in cancer cells, the normal DNA damage tolerance and response processes are disrupted or deregulated. This results in increased mutagenesis and genomic instability within the cancer cells, a known driver of cancer progression and therapeutic resistance. On the other hand, the inherent instability of the genome in rapidly dividing cancer cells can be exploited as a tool to kill by imposing DNA damage with radiopharmaceuticals. As the field of targeted radiopharmaceutical therapy (RPT) is rapidly growing in oncology, it is crucial to have a deep understanding of the impact of systemic radiation delivery by radiopharmaceuticals on the DNA of tumors and healthy tissues. The distribution and activation of DNA damage and repair pathways caused by RPT can be different based on the characteristics of the radioisotope and molecular target. Here we provide a comprehensive discussion of the biological effects of RPTs, with the main focus on the role of varying radioisotopes in inducing direct and indirect DNA damage and activating DNA repair pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
- Division of Hematology-Oncology, Department of Medicine, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
ORCID-Profile: Yousef Khazaei Monfared, Pedram Heidari, Umar Mahmood
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Khazaei Monfared, Y., Heidari, P., Klempner, S. J., Mahmood, U., Parikh, A. R., Hong, T. S., Strickland, M. R., & Esfahani, S. A. (2023). DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics, 15(12), 2761. https://doi.org/10.3390/pharmaceutics15122761
Vancouver
Khazaei Monfared Y, Heidari P, Klempner SJ, Mahmood U, Parikh AR, Hong TS, et al. DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics. 2023;15(12):2761. doi:10.3390/pharmaceutics15122761
BibTeX
@article{KhazaeiMonfared2023,
author = {Khazaei Monfared, Yousef and Heidari, Pedram and Klempner, Samuel J and Mahmood, Umar and Parikh, Aparna R and Hong, Theodore S and Strickland, Matthew R and Esfahani, Shadi A},
title = {DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {12},
pages = {2761},
doi = {10.3390/pharmaceutics15122761}
}
EUVIMED